Kyowa Kirin is continuing to monitor the COVID-19 outbreak. Learn More

Preparation and administration1

How to mix POTELIGEO

1.Visually inspect drug product solution for particulate matter and discoloration prior to administration. POTELIGEO is a clear to slightly opalescent colorless solution. Do not use the vial if cloudiness, discoloration, or particulates are observed.

2.Calculate the dose (mg/kg) and number of vials of POTELIGEO needed to prepare the infusion solution based on patient weight. Each vial contains 20 mg of POTELIGEO, which is enough for 20 kg of body weight.

3.Aseptically withdraw the required volume of POTELIGEO into the syringe and transfer into an intravenous (IV) baga containing 0.9% Sodium Chloride Injection, USP. The final concentration of the diluted solution should be between 0.1 mg/mL and 3.0 mg/mL.

4.Mix diluted solution by gentle inversion. Do not shake. After preparation, infuse the POTELIGEO solution immediately, or store under refrigeration at 2°C to 8°C (36°F to 46°F) for no more than 4 hours from the time of infusion preparation. Do not freeze. Do not shake.

5.Discard any unused portion left in the vial.

Administration

  • Administer infusion solution over at least 1 hour through an IV line containing a sterile, low protein binding, 0.22 micron (or equivalent) in-line filter
  • Do not mix POTELIGEO with other drugs
  • Calculate the dose (mg/kg) and number of vials of POTELIGEO needed to prepare the infusion solution based on patient weight
  • Do not co-administer other drugs through the same IV line
  • Prepared POTELIGEO is a clear to slightly opalescent colorless solution—without particulates

For more information on dosing, see the POTELIGEO Dosing and Administration Guide

Resource for you to use while counseling patients on what to expect during treatment,
see the POTELIGEO Patient Scheduling and Monitoring Treatment Guide

POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.

Important Safety Information

SEE LESS